Yogamet-GMP 2 Tablet is a combination oral antihyperglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The combination of these three agents offers a complementary mechanism of action, providing effective control of blood glucose in patients inadequately managed by monotherapy or dual therapy. Yogamet-GMP 2 Tablet is typically prescribed alongside diet and exercise to optimize glycemic control. It is essential to monitor blood glucose levels regularly and assess for potential adverse effects such as hypoglycemia, gastrointestinal disturbances, weight gain, and fluid retention. This medication should be used cautiously in patients with hepatic or renal impairment and contraindicated in those with severe heart failure or hypersensitivity to any component. Always consult a healthcare professional before initiating or adjusting therapy with Yogamet-GMP 2 Tablet.